Literature DB >> 19302262

Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease.

C Pande1, A Kumar, S K Sarin.   

Abstract

BACKGROUND: Small-intestinal bacterial overgrowth (SIBO) is known to be present in patients with cirrhosis, predisposing to various complications. AIM: To determine the frequency of SIBO in cirrhotics and correlate with severity of cirrhosis.
METHODS: Small-intestinal bacterial overgrowth was determined by glucose-hydrogen breath test (GHBT). A basal breath-hydrogen >20 ppm or a rise by > or = 12 ppm above baseline following glucose administration was taken as positive test. Prevalence of SIBO in cirrhotics was compared with healthy controls and correlated with severity of cirrhosis.
RESULTS: Of the 53 cirrhotics, 26 (49%) had SIBO, compared to one (8%) control (P = 0.010). The prevalence of SIBO increased with severity of cirrhosis (Child-Pugh A 20%, B 52% and C 73%; P = 0.013). On multivariate analysis, SIBO was independently associated with serum bilirubin and ascites. The best cut-off of serum bilirubin was >/=2 mg/dL [AUROC 0.77 (95% CI 0.64-0.90)] predicting SIBO with sensitivity 65%, specificity 81%, positive predictive value 77%, negative predictive value 71% and accuracy 74%. Patients having combination of ascites and serum bilirubin > or = 2 mg/dL had 82% chance, while patients having neither had only 10% chance of having SIBO.
CONCLUSIONS: Small-intestinal bacterial overgrowth was prevalent in about half of cirrhotics. Its frequency increased with increase in severity of cirrhosis. Ascites and raised serum bilirubin reliably predicted presence of SIBO.

Entities:  

Mesh:

Year:  2009        PMID: 19302262     DOI: 10.1111/j.1365-2036.2009.03994.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  54 in total

1.  Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Turk J Gastroenterol       Date:  2019-11       Impact factor: 1.852

2.  Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

3.  Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.

Authors:  Yuying Zhang; Yikuan Feng; Bin Cao; Qiang Tian
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  Gut microbiota: its role in hepatic encephalopathy.

Authors:  Rahul Rai; Vivek A Saraswat; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-16

Review 5.  Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

Authors:  Philipp Lutz; Hans Dieter Nischalke; Christian P Strassburg; Ulrich Spengler
Journal:  World J Hepatol       Date:  2015-03-27

Review 6.  Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Davide Roccarina; Francesca Romana Ponziani; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

Review 7.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 8.  Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis.

Authors:  Charlotte Woodhouse; Arjuna Singanayagam; Vishal C Patel
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

9.  Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Hepatol Int       Date:  2018-10-04       Impact factor: 6.047

10.  Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease.

Authors:  Andre Fialho; Andrea Fialho; Gursimran Kochhar; Aldo L Schenone; Prashanti Thota; Arthur J McCullough; Bo Shen
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.